MedWatch

2curex finds partner for Polish launch

Danish 2curex is now ready to launch its cancer test, Inditreat, in Poland, where a new partnership with a local firm will bring the tool to Polish oncologists.

Photo: 2curex / PR

Polish firm Perlan Technologies and 2curex have signed an agreement entailing the launch of the Danish firm's cancer test, Inditreat, on the Polish market, 2curex announces in a press release.

Under terms of the deal, Perlan is tasked with the domestic marketing of Inditreat which tests a patient's tumor and predicts tumor responses to different drugs, providing information to physicians about individual patient treatments.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs